IP Library Granted Patent US 6,977,169
Granted Patent B2
US 6,977,169 · App. 09/827,302 · Granted Dec 20, 2005

Methods and compositions for treating neoplasms

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 6,977,169
App. No.
09/827,302
Granted
Dec 20, 2005
Kind
B2
Abstract

The present invention comprises the periodic administration of a solution of neuraminidase to a patient with a neoplasm until the neoplasm has receded. The administration of the solution of neuraminidase can be administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration. The present invention is effective in treating a wide variety of neoplasms.

Claims (13)

1. A method for treating a human with cancer, comprising administering to the human with cancer a composition comprising between approximately 10 −2 mg to approximately 10 −8 mg of neuraminidase, wherein the method further comprises multiple per day administrations of the composition.

2. The method of claim 1 , wherein the composition comprises neuraminidase dissolved in a phenol-saline solution.

3. The method of claim 1 , wherein the neuraminidase composition is administered systemically.

4. The method of claim 1 , wherein the neuraminidase composition is administered by subcutaneous injection, intramuscular injection, intravenous injection, nasal administration, sublingual administration or transdermal administration.

5. The method of claim 4 , wherein the neuraminidase composition is administered sublingually.

6. The method of claim 4 , wherein the neuraminidase composition is administered nasally.

7. The method of claim 1 , wherein cancer is a solid tumor.

8. The method of claim 7 , wherein cancer is prostate cancer, pancreatic cancer, melanoma, breast cancer, colon cancer, lymphoma, esophageal cancer, lung cancer, testicular cancer, or brain cancer.

9. The method of claim 1 , wherein less than approximately 10 −2 mg neuraminidase is administered.

10. The method of claim 1 , wherein approximately 10 −4 mg to 10 −8 mg neuraminidase is administered.

11. The method of claim 1 , wherein approximately 10 −4 mg neuraminidase is administered.

12. The method of claim 1 , wherein the neuraminidase is administered one to eight times per day.

13. A method for treating a human with cancer, comprising administering to the human a composition consisting essentially of between approximately 10 −2 mg to approximately 10 −8 mg of neuramiidase wherein the method further comprises multiple per day administrations of the composition.

Assignments (3)
SECURITY AGREEMENT Recorded May 3, 2012
From: SIGNAL COORDINATING THERAPY, INC.
To: BRANDT, WILLIAM F., JR.
Reel/Frame 028151/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 17, 2006
From: MOLECULAR RX, INC.
To: SIGNAL COORDINATING THERAPY, INC.
Reel/Frame 017675/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2006
From: KLINE, ELLIS L.
To: MOLECULAR RX, INC.
Reel/Frame 017619/0113 →
Continuity (2)
Provisional Application 6019553800 · Apr 7, 2000
Related Publication 20010036455A1 · Nov 1, 2001